Back to News
Market Impact: 0.4
Disc Medicine Reports Positive Phase 2 RESTORE-PV Data For DISC-3405 In Polycythemia Vera
Source: Nasdaq
Healthcare & BiotechProduct Launches
Disc Medicine presented positive initial Phase 2 RESTORE-PV results for DISC-3405 in patients with polycythemia vera at the 2026 SOHO annual meeting. The clinical update supports the development outlook for the company’s lead PV candidate, though the article provided no efficacy, safety, or statistical-result magnitudes.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
IRON0.78
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- J&J prostate cancer drug shows promising tumor responses in early trial
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine
- Fact vs. fiction: Doctors share whether peptides are safe and effective
- Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer